Author(s): Rolfs, Prof. Arndt, MD, Kretzschmar, Christin, Roolf, Catrin, PhD, Langhammer, Tina-Susann, Sekora, Anett, Pews-Davtyan, Anahit, MD, Beller, Prof. Matthias, PhD, Frech, Moritz J, PhD, Eisenlöffel, Christian, Junghanss, Prof. Christian, MD
In this publication we evaluated the influence of a novel arylindolylmaleimide (PDA-66), a potential GSK3β inhibitor, on several ALL cell lines. Read more!
PDA-66 displays significant antileukemic activity in ALL cells and classifies as candidate for further evaluation as a potential drug in targeted therapy of ALL.
Read publication (PDF)
